Avi BioPharma

Avi BioPharma licenses vascular disease program to Cook Group

Published in Medicine and Law Weekly, September 8th, 2006

Avi BioPharma, Inc. (AVII) issued an update on its licensed and internal cardiovascular programs, both of which have been strengthened by notices of allowance from the U.S. Patent Office.

Avi licensed its vascular disease program to the Cook Group, Inc., (Cook) in March 2006 for device delivery of the NeuGene antisense drug Avi-4126, while the company is focusing internal development on coronary artery bypass graft (CABG) using Avi-5126. The following patents were the subject of the U.S. Patent Office's notification:

"Antisense Restenosis Composition and Method" covers the broad use of Avi-4126 to treat any vascular injury including balloon...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medicine and Law Weekly

Source: Medicine and Law Weekly (2006-09-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry